Addex Therapeutics (ADXN) Net Cash Flow (2019 - 2026)
Addex Therapeutics (ADXN) posted Net Cash Flow of -$894.4 billion for Q1 2026, down 247.89% sequentially from $604.8 billion in Q2 2025, and down 60.6% YoY from -$2270.4 billion in Q1 2025.
Addex Therapeutics (ADXN) Net Cash Flow (2019 - 2026) Analysis & Trends
Addex Therapeutics has reported Net Cash Flow for 8 years, with the latest figure at -$894.4 billion in Q1 2026.
- Quarterly Net Cash Flow fell 60.6% year-over-year to -$894.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$289.6 billion (down 117.24% YoY) and the FY2025 annual result came in at -$2.0 million, down 183.89% from the prior year.
- Net Cash Flow slipped to -$894.4 billion in Q1 2026 per ADXN's latest filing, from $604.8 billion in the prior quarter.
- Over five years, Net Cash Flow peaked at $2313.4 billion in Q4 2023 and troughed at -$2764.5 billion in Q3 2023.
- A 5-year average of -$63.5 billion and a median of -$3.4 million in 2022 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 68771161.25% in 2023, down 178495159.36% in 2023.
- Over 5 years, Net Cash Flow stood at -$3.4 million in 2022, then soared by 68771161.25% to $2313.4 billion in 2023, then tumbled by 71.27% to $664.6 billion in 2024, then fell by 9.0% to $604.8 billion in 2025, then slumped by 247.89% to -$894.4 billion in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$894.4 billion, $604.8 billion, and -$556.9 billion for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | -894.44 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -894.44 Bn |
| Mar 31, 2026 | -894.44 Bn |
| Jun 30, 2025 | 604.81 Bn |
| Jun 30, 2025 | 604.81 Bn |
| Mar 31, 2025 | -556.92 Bn |
| Mar 31, 2025 | -556.92 Bn |
| Dec 31, 2024 | 664.64 Bn |
| Dec 31, 2024 | 664.64 Bn |
| Sep 30, 2024 | -672.03 Bn |
| Sep 30, 2024 | -672.03 Bn |
| Jun 30, 2024 | 2,244.57 Bn |
| Jun 30, 2024 | 2,244.57 Bn |
| Mar 31, 2024 | -2,325.54 Bn |
| Mar 31, 2024 | -2,325.54 Bn |
| Dec 31, 2023 | 2,313.41 Bn |
| Dec 31, 2023 | 2,313.41 Bn |
| Sep 30, 2023 | -2,764.45 Bn |
| Sep 30, 2023 | -2,764.45 Bn |
| Jun 30, 2023 | 433.41 Bn |
| Jun 30, 2023 | 433.41 Bn |